The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective

References

• International Diabetes Federation. Diabetes Data Report. 2000–2045; [cited 2022 Oct 20]. 2022. Available from: https://diabetesatlas.org/data/en/world/
   Google Scholar
• American Diabetes Association. Statistics About Diabetes; [cited 2022 Oct 14; updated 2022 Jul 28]. 2022. Available from: https://diabetes.org/about-us/statistics/about-diabetes
   Google Scholar
• Shi L, Fonseca V, Childs B. Economic burden of diabetes-related hypoglycemia on patients, payors, and employers. J Diabetes Complications. 2021;35(6):107916. doi: 10.1016/j.jdiacomp.2021.107916.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–928. doi: 10.2337/dci18-0007.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559. doi: 10.1056/NEJMoa0802743.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139. doi: 10.1056/NEJMoa0808431.
   PubMed Web of Science ®Google Scholar
• Hayward RA, Reaven PD, Emanuele NV, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372(23):2197–2206. doi: 10.1056/NEJMc1508386.
   PubMed Web of Science ®Google Scholar
• Reaven PD, Emanuele NV, Wiitala WL, et al. Intensive glucose control in patients with type 2 diabetes - 15-Year follow-up. N Engl J Med. 2019;380(23):2215–2224. doi: 10.1056/NEJMoa1806802.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American diabetes association and the european association for the study of diabetes. Diabetes Care. 2006;29(8):1963–1972. doi: 10.2337/dc06-9912.
   PubMed Web of Science ®Google Scholar
• Harris SB, Parente EB, Karalliedde J. Clinical use of insulin glargine 300 U/mL in adults with type 2 diabetes: hypothetical case studies. Diabetes Ther. 2022;13(5):913–930. doi: 10.1007/s13300-022-01247-7.
   PubMed Web of Science ®Google Scholar
• Rowley WR, Bezold C, Arikan Y, et al. Diabetes 2030: insights from yesterday, today, and future trends. Popul Health Manag. 2017;20(1):6–12. doi: 10.1089/pop.2015.0181.
   PubMed Web of Science ®Google Scholar
• Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002;45(7):937–948. doi: 10.1007/s00125-002-0822-9.
   PubMed Web of Science ®Google Scholar
• Sussman M, Sierra JA, Garg S, et al. Economic impact of hypoglycemia among insulin-treated patients with diabetes. J Med Econ. 2016;19(11):1099–1106. doi: 10.1080/13696998.2016.1201090.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 2021;9(8):525–544. doi: 10.1016/S2213-8587(21)00113-3.
   PubMed Web of Science ®Google Scholar
• Home P, Riddle M, Cefalu WT, et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care. 2014;37(6):1499–1508. doi: 10.2337/dc13-2743.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the european association for the study of diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701. doi: 10.2337/dci18-0033.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107–139. doi: 10.4158/CS-2019-0472.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the european association for the study of diabetes. Diabetes Care. 2015;38(1):140–149. doi: 10.2337/dc14-2441.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice C. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125–S143. doi: 10.2337/dc22-S009.
   PubMedGoogle Scholar
• Cheng A, Bailey TS, Mauricio D, et al. Insulin glargine 300 U/mL and insulin degludec: a review of the current evidence comparing these two second-generation basal insulin analogues. Diabetes Metab Res Rev. 2020;36(7):e3329. doi: 10.1002/dmrr.3329.
   PubMed Web of Science ®Google Scholar
• Hernando VU, Pablo FJ. Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: a critical appraisal. Diabetes Metab Syndr. 2019;13(3):2126–2141. doi: 10.1016/j.dsx.2019.05.001.
   PubMedGoogle Scholar
• Blonde L, Bailey T, Sullivan SD, et al. Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: a review of the DELIVER programme. Diabetes Obes Metab. 2021;23(8):1713–1721. doi: 10.1111/dom.14405.
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Bergenstal RM, Bolli GB, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab. 2015;17(12):1142–1149. doi: 10.1111/dom.12532.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755–2762. doi: 10.2337/dc14-0991.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17(4):386–394. doi: 10.1111/dom.12438.
   PubMed Web of Science ®Google Scholar
• Terauchi Y, Koyama M, Cheng X, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab. 2016;18(4):366–374. doi: 10.1111/dom.12618.
   PubMed Web of Science ®Google Scholar
• Bailey TS, Wu J, Zhou FL, et al. Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3). Diabetes Obes Metab. 2019;21(11):2384–2393. doi: 10.1111/dom.13818.
   PubMed Web of Science ®Google Scholar
• Zhou FL, Ye F, Berhanu P, et al. Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin. Diabetes Obes Metab. 2018;20(5):1293–1297. doi: 10.1111/dom.13199.
   PubMed Web of Science ®Google Scholar
• Pettus J, Roussel R, Liz Zhou F, et al. Rates of hypoglycemia predicted in patients with type 2 diabetes on insulin glargine 300 U/ml versus first- and Second-Generation basal insulin analogs: the Real-World LIGHTNING study. Diabetes Ther. 2019;10(2):617–633. doi: 10.1007/s13300-019-0568-8.
   PubMed Web of Science ®Google Scholar
• Napoli R, Fanelli F, Gazzi L, et al. Using 2nd generation basal insulins in type 2 diabetes: costs and savings in a comparative economic analysis in Italy, based on the BRIGHT study. Nutr Metab Cardiovasc Dis. 2020;30(11):1937–1944. doi: 10.1016/j.numecd.2020.07.005.
   PubMed Web of Science ®Google Scholar
• United States Census Bureau. National Population by Characteristics. 2020-2021; [cited 2022 Spt 2]. 2022. Avialble from: https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html
   Google Scholar
• Higuchi KN, Wu J, Gill J, et al. Lower Healthcare-Resource Utilization and Associated Costs in Insulin-Naïve Patients With Type 2 Diabetes Initiated on Insulin Glargine 300 U/mL. Sanofi data on file. Virtual poster session presented at: AMCP Nexus.2020 Oct 20-23. Available from: https://www.jmcp.org/doi/pdf/10.18553/jmcp.2020.26.issue-10-a
   Google Scholar
• U.S. Bureau of Labor Statistics. Databases, Tables, and Calculators by Subject; [cited 2023 June 22]. Available from https://data.bls.gov/timeseries/CUUR0000SAM2
   Google Scholar
• Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–1507. doi: 10.1016/S0140-6736(12)60205-0.
   PubMed Web of Science ®Google Scholar
• Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN once long). Diabetes Care. 2012;35(12):2464–2471. doi: 10.2337/dc12-1205.
   PubMed Web of Science ®Google Scholar
• Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36(9):2536–2542. doi: 10.2337/dc12-2329.
   PubMed Web of Science ®Google Scholar
• Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36(4):858–864. doi: 10.2337/dc12-1668.
   PubMed Web of Science ®Google Scholar
• Onishi Y, Iwamoto Y, Yoo SJ, et al. Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig. 2013;4(6):605–612. doi: 10.1111/jdi.12102.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Cheng A, Ritzel R, et al. More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in Insulin-Naive type 2 diabetes: the randomized head-to-Head BRIGHT trial. Diabetes Care. 2018;41(10):2147–2154. doi: 10.2337/dc18-0559.
   PubMed Web of Science ®Google Scholar
• Bailey TS, Zhou FL, Gupta RA, et al. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: real-world results from the DELIVER naive cohort study. Diabetes Obes Metab. 2019;21(7):1596–1605. doi: 10.1111/dom.13693.
   PubMed Web of Science ®Google Scholar
• Sayed BA, Finegold K, et al. Insulin Affordability and the Inflation Reduction Act: medicare Beneficiary Savings by State and Demographics. (Issue Brief No. HP-2023-02). Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. 2023.
   Google Scholar
• Azzoug SL, Aissaoui A, Hachelaf Z. Budget Impact Analysis of Insulin Glargine-300U/mL (Gla-300) for Treatment of T1DM and T2DM in Adults Population in Algerian Setting. Poster session presented at: ISPOR Europe, 2022 Nov 6–9; Vienna, Austria. 2022.
   Google Scholar
• Wright EE, Jr., Malone DC, Trujillo JM, et al. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin. J Manag Care Spec Pharm. 2022;28(6):592–603. doi: 10.18553/jmcp.2022.21436.
   PubMed Web of Science ®Google Scholar